Last reviewed · How we verify

NCT04427033

The BCI 602 BONEBRIDGE Post-Market Clinical Follow-up Study

Completed Last updated 25 January 2024
What this trial tests

trial testing Bone Conduction Implant in Hearing Loss in 52 participants. Completed in 18 January 2024.

Timeline
6 December 2019
Primary endpoint
18 January 2024
18 January 2024

Quick facts

Lead sponsorMED-EL Elektromedizinische Geräte GesmbH
StatusCompleted
Study typeOBSERVATIONAL
Enrollment52
Start date6 December 2019
Primary completion18 January 2024
Estimated completion18 January 2024
Sites8 locations across Austria, United Kingdom, Germany

Drugs / interventions tested

Conditions studied

Sponsor

MED-EL Elektromedizinische Geräte GesmbH — full company profile →

Who can join

5 and older, any sex, with Hearing Loss or Hearing Loss, Conductive. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The Bonebridge system using the BCI 601 is marketed since 2012. Previous prospective, multi-center, non-randomized studies on the BCI 601 Bonebridge performed in adult and paediatric populations have shown a significant improvement in terms of aided sound field (SF) thresholds, word recognition scores (WRS), speech reception thresholds (SRT) and subjective device satisfaction. Safety was established by stable residual hearing and low complication rates. The Bonebridge, implanted in over 600 clinics worldwide, is the world's first active transcutaneous bone conduction implant (BCI) system. This study now focuses on the further developed BCI 602 (marketed since 2019) that has the same indication criteria and performance characteristics. The aim of this post-market clinical follow-up (PMCF) study is to provide clinical data for the long-term performance and safety when implanted with the Bonebridge BCI 602 .

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Multicentric study on surgical information and early safety and performance results with the Bonebridge BCI 602: an active transcutaneous bone conduction hearing implant.
    Sprinzl G, Toner J, Koitschev A, Berger N, et al · · 2023 · cited 16× · PMID 36625869 · DOI 10.1007/s00405-022-07792-y
  2. The Bonebridge BCI 602 Safety and Performance 1 Year Post-Implantation in Adults and Children: A Multicentric Post-Market Study.
    Plontke SK, Lenarz T, Toner J, Keintzel T, et al · · 2026 · PMID 41250191 · DOI 10.1097/mao.0000000000004688

Verify or expand the search:

Other recruiting trials for Hearing Loss

Currently open trials in the same condition.

Other MED-EL Elektromedizinische Geräte GesmbH trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04427033.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing